Shu Jun, Ren Ning, Du Ji-Bing, Zhang Mei, Cong Hong-Liang, Huang Ti-Gang
Department of Cardiology, 2nd Hospital, Tianjin Medical University, Tianjin, PR China.
Scand Cardiovasc J. 2007 Jun;41(3):149-54. doi: 10.1080/14017430601164263.
To investigate the association between inflammatory mediators, matrix degrading enzymes and acute coronary syndrome (ACS) and the impact of early reperfusion therapy on circulating biomarkers.
Peripheral serum levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) were determined in 134 patients with ACS. These biomarkers were serially monitored in ten patients with intravenous thrombolytic therapy (IVT).
Serum levels of IL-6, hs-CRP and MMP-9 were higher in unstable angina (UA) and myocardial infarction (MI) groups than in control or SA group (p<0.05). Peripheral IL-6 level in patients with MI was greater after percutaneous coronary intervention (PCI) (p<0.01) or IVT (p<0.05). Serial concentration determination revealed marked elevation of serum IL-6 and MMP-9 levels, both reaching peak values (like creatine kinase-MB).
Elevated levels of IL-6, hs-CRP and MMP-9 provide a link between inflammation, matrix degradation and the development and progression of ACS. IL-6 and MMP-9 appear to be released mainly from vulnerable plaque or necrotic myocardium during the acute phase of MI.
研究炎症介质、基质降解酶与急性冠状动脉综合征（ACS）之间的关联，以及早期再灌注治疗对循环生物标志物的影响。
测定134例ACS患者外周血清白细胞介素-6（IL-6）、高敏C反应蛋白（hs-CRP）和基质金属蛋白酶-9（MMP-9）水平。对10例接受静脉溶栓治疗（IVT）的患者进行这些生物标志物的连续监测。
不稳定型心绞痛（UA）和心肌梗死（MI）组的血清IL-6、hs-CRP和MMP-9水平高于对照组或稳定型心绞痛（SA）组（p<0.05）。MI患者经皮冠状动脉介入治疗（PCI）后（p<0.01）或IVT后（p<0.05）外周血IL-6水平更高。连续浓度测定显示血清IL-6和MMP-9水平显著升高，均达到峰值（如肌酸激酶-MB）。
IL-6、hs-CRP和MMP-9水平升高为炎症、基质降解与ACS的发生和发展之间提供了联系。IL-6和MMP-9似乎主要在MI急性期从易损斑块或坏死心肌中释放出来。
